Table 3.

Patient outcomes from time of AHCT

	Bortezomib induction (N = 294)		No Induction (N = 146)
Outcomes	N	Prob (95% CI)	N	Prob (95% CI)	P-value
Transplant-related mortality	288		145
100-day		2 (1–4)%		3 (1–7)%	0.43
Hematologic Relapse/Progression	288		145		0.02
1-year		8 (5–11)%		15 (9–21)%	0.04
2-year		13 (9–18)%		23 (16–32)%	0.02
Progression-free survival	288		145		<0.01
1-year		90 (86–93)%		79 (72–85)%	<0.01
2-year		82 (77–87)%		69 (61–77)%	0.01
Overall survival	294		146		0.22
1-year		95 (93–98)%		91 (86–95)%	0.13
2-year		92 (88–95)%		89 (84–94)%	0.47